Safety of Bioelectrical Impedance Analysis in Patients Equipped With Implantable Cardioverter Defibrillators

JPEN J Parenter Enteral Nutr. 2017 Aug;41(6):981-985. doi: 10.1177/0148607116633823. Epub 2016 Feb 22.

Abstract

Background: Current guidelines warn of potential electromagnetic interferences (EMI) when using bioelectrical impedance analysis (BIA) to measure body composition in patients equipped with implantable cardioverter-defibrillators (ICDs). We aimed to test the occurrence of EMI in a setting where this risk was experimentally maximized.

Materials and methods: Outpatients scheduled for routine ICD controls simultaneously underwent a BIA measurement using an electrical current of 0.8 mAmp at frequencies from 5-100 kHz. ICD sensitivity levels were set to maximum levels while therapies were temporarily inactivated. The device electrograms were monitored in real time to detect sensed and/or visible EMI during BIA measurement.

Results: A total of 63 patients equipped with single-chamber (n = 13), dual-chamber (n = 18), or biventricular (n = 32) ICDs from 5 major manufacturers were included. No EMI were detected by the ICDs in these patients, nor were any artifacts visualized during real-time electrogram recordings.

Conclusion: BIA can be safely performed in patients equipped with ICDs without cardiac monitoring. Current guidelines should be updated accordingly.

Trial registration: ClinicalTrials.gov NCT02349737.

Keywords: bioelectrical impedance analysis; heart failure; implantable cardioverter-defibrillator.

MeSH terms

  • Aged
  • Body Composition
  • Body Mass Index
  • Cardiac Resynchronization Therapy Devices*
  • Chronic Disease
  • Defibrillators, Implantable*
  • Electric Impedance*
  • Electromagnetic Phenomena
  • Female
  • Heart Failure / complications
  • Heart Failure / therapy*
  • Humans
  • Male
  • Middle Aged
  • Monitoring, Physiologic
  • Prospective Studies
  • Risk Factors

Associated data

  • ClinicalTrials.gov/NCT02349737